US Cell and Gene Therapy Market Size, Share, and Trends 2026 to 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on US Cell and Gene Therapy Market 

5.1. COVID-19 Landscape: US Cell and Gene Therapy Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. US Cell and Gene Therapy Market, By Therapy Type

8.1. US Cell and Gene Therapy Market, by Therapy Type

8.1.1. Cell Therapy

8.1.1.1. Market Revenue and Forecast

8.1.2. Gene Therapy

8.1.2.1. Market Revenue and Forecast

Chapter 9. US Cell and Gene Therapy Market, By Indication / Therapeutic Area

9.1. US Cell and Gene Therapy Market, by Indication / Therapeutic Area

9.1.1. Oncology

9.1.1.1. Market Revenue and Forecast

9.1.2. Genetic Disorders

9.1.2.1. Market Revenue and Forecast

9.1.3. Neurological Disorders

9.1.3.1. Market Revenue and Forecast

9.1.4. Cardiovascular Diseases

9.1.4.1. Market Revenue and Forecast

9.1.5. Ophthalmology

9.1.5.1. Market Revenue and Forecast

Chapter 10. US Cell and Gene Therapy Market, By Vector Type (Gene Delivery Method) 

10.1. US Cell and Gene Therapy Market, by Vector Type (Gene Delivery Method)

10.1.1. Viral Vectors

10.1.1.1. Market Revenue and Forecast

10.1.2. Non-Viral Vectors

10.1.2.1. Market Revenue and Forecast

Chapter 11. US Cell and Gene Therapy Market, By Manufacturing Type

11.1. US Cell and Gene Therapy Market, by Manufacturing Type

11.1.1. In-house (Biotech/Pharma-Owned Facilities)

11.1.1.1. Market Revenue and Forecast

11.1.2. Contract Development & Manufacturing Organizations (CDMOs)

11.1.2.1. Market Revenue and Forecast

11.1.3. Hybrid Models (e.g., early stage in-house, scale-up outsourced)

11.1.3.1. Market Revenue and Forecast

11.1.4. Others

11.1.4.1. Market Revenue and Forecast

Chapter 12. US Cell and Gene Therapy Market, By End User

12.1. US Cell and Gene Therapy Market, by End User

12.1.1. Hospitals and Specialty Clinics (administering therapies)

12.1.1.1. Market Revenue and Forecast

12.1.2. Academic and Research Institutes (preclinical development)

12.1.2.1. Market Revenue and Forecast

12.1.3. Biopharma and Biotech Companies

12.1.3.1. Market Revenue and Forecast

12.1.4. CDMOs and CROS

12.1.4.1. Market Revenue and Forecast

12.1.5. Government/Public Health Bodies (NIH, EMA programs)

12.1.5.1. Market Revenue and Forecast

Chapter 13. US Cell and Gene Therapy Market, Regional Estimates and Trend Forecast

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Therapy Type

13.1.6.2. Market Revenue and Forecast, by Indication / Therapeutic Area

13.1.6.3. Market Revenue and Forecast, by Vector Type (Gene Delivery Method)

13.1.6.4. Market Revenue and Forecast, by Manufacturing Type

13.1.6.5. Market Revenue and Forecast, by End User 

Chapter 14. Company Profiles

14.1. Alnylam Pharmaceuticals Inc.

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Amgen Inc.

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Biogen Inc.

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. CORESTEM Inc.

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Dendreon Pharmaceuticals LLC.

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Helixmith Co. Ltd.

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. JCR Pharmaceuticals Co. Ltd.

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Kolon TissueGene Inc.

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Novartis AG

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Pfizer Inc.

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms